Titre du document / Document title

Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction : Results from a randomized, double-blind, placebo-controlled trial

Auteur(s) / Author(s)

FAVA Maurizio ⁽¹⁾ ; GEORGE NURNBERG H. ⁽²⁾ ; SEIDMAN Stuart N. ⁽³⁾ ; HOLLOWAY Willis ⁽⁴⁾ ; NICHOLAS Susan ⁽⁵⁾ ; TSENG Li-Jung ⁽⁵⁾ ; STECHER Vera J. ⁽⁵⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Depression Clinical and Research Program, the Department of Psychiatry, Massachusetts General Hospital, Boston, ETATS-UNIS
⁽²⁾ Department of Psychiatry, University of New Mexico, Albuquerque, ETATS-UNIS
⁽³⁾ Department of Psychiatry, Columbia Presbyterian Medical Center, New York, N.Y, ETATS-UNIS
⁽⁴⁾ Cutting Edge Research, Oklahoma City, Okla, ETATS-UNIS
⁽⁵⁾ Pfizer Inc, New York, N.Y, ETATS-UNIS

Résumé / Abstract

Objective: To evaluate the efficacy of short-term treatment with sildenafil citrate in men with serotonin reuptake inhibitor (SRI)-associated erectile dysfunction (ED). Method: Men (aged ≥ 18 years) with major depressive disorder (MDD; DSM-IV criteria) in remission and taking SRIs who experienced SRI-associated ED were enrolled in this multicenter, 6-week, randomized, flexible-dose, double-blind, placebo-controlled trial. The primary study measures were questions 3 (Q3: frequency of penetration) and 4 (Q4: frequency of maintained erections after penetration) of the International Index of Erectile Function (IIEF) questionnaire. Secondary study measures were all other questions and domains of the IIEF, the Erectile Dysfunction Index of Treatment Satisfaction (EDITS), a global efficacy questionnaire (GEQ), and a patient-maintained event log of sexual activity. Results: Patients receiving sildenafil (N =71) versus placebo (N = 71) reported significantly higher mean ± SE scores on Q3 (3.9 ± 0.2 vs. 3.1 ± 0.2, p =.003) and Q4 (3.7 ± 0.2 vs. 2.8 ± 0.2, p <.001) of the IIEF and significantly higher scores on all domains of the IIEF. Patients receiving sildenafil also reported significantly improved scores on all questions of the EDITS questionnaire (p <.02) and the GEQ (p <.0001) and an increased number of successful sexual intercourse attempts per week (p <.0001) compared with patients receiving placebo. All patients remained in MDD remission (score ≤ 10 on the Hamilton Rating Scale for Depression). Adverse events in patients taking sildenafil (vs. placebo) were headache (9% vs. 9%), dyspepsia (9% vs. 1%), anxiety (6% vs. 4%), and abnormal vision (3% vs. 0%). Conclusions: Short-term (6-week) administration of sildenafil was well tolerated and significantly improved erectile function and overall sexual satisfaction in men with ED associated with SRI therapy for MDD. Sildenafil may be successfully used to treat SRI-associated ED without interruption of antidepressant therapy.

Revue / Journal Title

The Journal of clinical psychiatry    ISSN  0160-6689 

Source / Source

2006, vol. 67, n^o2, pp. 240-246 [7 page(s) (article)] (38 ref.)

Langue / Language

Anglais

Editeur / Publisher

Physicians Postgraduate Press, Memphis, TN, ETATS-UNIS  (1978) (Revue)

Mots-clés anglais / English Keywords

Male genital diseases

;

Enzyme inhibitor

;

Enzyme

;

Hydrolases

;

Esterases

;

Phosphoric diester hydrolases

;

3',5'-Cyclic-GMP phosphodiesterase

;

Vasodilator agent

;

Male

;

Human

;

Placebo

;

Double blind study

;

Erection disorders

;

Psychotropic

;

Treatment

;

Chemotherapy

;

Antidepressant agent

;

Sildenafil

;

Safety

;

Mots-clés français / French Keywords

Inhibiteur de la phosphodiestérase 5

;

Inhibiteur phosphodiesterase

;

Appareil génital mâle pathologie

;

xWww Resultspharmacy Channel 11 Safety Sildenafil Citrate Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction : Results from a randomized, double-blind, placebo-controlled trialj f Sildenafil Safety Sildenafil Citrate iWww Resultspharmacy Channel 11 Safety Sildenafil Citrate Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction : Results from a randomized, double-blind, placebo-controlled trialg n Safety Sildenafil Citrate